Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies

European Journal of Clinical Investigation

Volumn 42, Issue 8, 2012, Pages 815-822

  Voumvouraki, Argyro ^a,b   Notas, George ^b   Koulentaki, Mairi ^a   Georgiadou, Maria ^b   Klironomos, Stefanos ^b   Kouroumalis, Elias ^a,b  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Activin A; Alcoholic cirrhosis; Hepatocellular carcinoma; Viral cirrhosis

Indexed keywords

ACTIVIN A;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ALCOHOLIC FATTY LIVER; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATIC VEIN; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACTIVINS; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 84863992200     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02647.x     Document Type: Article

References (52)

1. Rodgarkia-Dara C, Vejda S, Erlach N, Losert A, Bursch W, Berger W et al. The activin axis in liver biology and disease. Mutat Res 2006;613:123-37.
2. Mason AJ, Hayflick JS, Ling N, Esch F, Ueno N, Ying SY et al. Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-beta. Nature 1985;318:659-63.
3. Todorovic V, Jurukovski V, Chen Y, Fontana L, Dabovic B, Rifkin DB. Latent TGF-beta binding proteins. Int J Biochem Cell Biol 2005;37:38-41.
4. Vejda S, Cranfield M, Peter B, Mellor SL, Groome N, Schulte-Hermann R et al. Expression and dimerization of the rat activin subunits betaC and betaE: evidence for the formation of novel activin dimers. J Mol Endocrinol 2002;28:137-48.
5. Tuuri T, Eramaa M, Hilden K, Ritvos O. The tissue distribution of activin beta A- and beta B-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development. J Clin Endocrinol Metab 1994;78:1521-4.
6. Werner S, Alzheimer C. Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev 2006;17:157-71.
7. Beattie GM, Lopez AD, Bucay N, Hinton A, Firpo MT, King CC et al. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells (Dayton, Ohio) 2005;23:489-95.
8. Chen YG, Wang Q, Lin SL, Chang CD, Chuang J, Ying SY. Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis. Exp Biol Med (Maywood, N.J) 2006;231:534-44.
9. Abe Y, Minegishi T, Leung PC. Activin receptor signaling. Growth Factors (Chur, Switzerland) 2004;22:105-10.
10. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
11. Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 2007;104:16239-44.
12. Gold EJ, Francis RJ, Zimmermann A, Mellor SL, Cranfield M, Risbridger GP et al. Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis. Mol Cell Endocrinol 2003;201:143-53.
13. Huang X, Li DG, Wang ZR, Wei HS, Cheng JL, Zhan YT et al. Expression changes of activin A in the development of hepatic fibrosis. World J Gastroenterol 2001;7:37-41.
14. Valatas V, Kolios G, Manousou P, Notas G, Xidakis C, Diamantis I et al. Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. Br J Pharmacol 2004;141:477-87.
15. Valatas V, Kolios G, Manousou P, Xidakis C, Notas G, Ljumovic D et al. Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide. Regul Pept 2004;120:215-25.
16. Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011;17:313-21.
17. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7.
18. Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci 2008;53:2359-65.
19. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
20. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch 1978;379:103-12.
21. Yuen MF, Norris S, Evans LW, Langley PG, Hughes RD. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol 2002;37:233-8.
22. Patella S, Phillips DJ, de Kretser DM, Evans LW, Groome NP, Sievert W. Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis. J Hepatol 2001;34:576-83.
23. Yndestad A, Haukeland JW, Dahl TB, Bjoro K, Gladhaug IP, Berge C et al. A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol 2009;104:2196-205.
24. Date M, Matsuzaki K, Matsushita M, Tahashi Y, Sakitani K, Inoue K. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. J Hepatol 2000;32:251-60.
25. Sugiyama M, Ichida T, Sato T, Ishikawa T, Matsuda Y, Asakura H. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology 1998;114:550-8.
26. Lee DK, Park SH, Yi Y, Choi SG, Lee C, Parks WT et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev 2001;15:455-66.
27. Wada W, Kuwano H, Hasegawa Y, Kojima I. The dependence of transforming growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology 2004;145:2753-9.
28. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM. Intracrine signalling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression. Liver Int 2008;28:1207-16.
29. Patella S, Phillips DJ, Tchongue J, de Kretser DM, Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol 2006;290:G137-44.
30. Pirisi M, Fabris C, Luisi S, Santuz M, Toniutto P, Vitulli D et al. Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma. Cancer Detect Prev 2000;24:150-5.
31. Elsammak MY, Amin GM, Khalil GM, Ragab WS, Abaza MM. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis. Clin Biochem 2006;39:623-9.
32. Risbridger GP, Schmitt JF, Robertson DM. Activins and inhibins in endocrine and other tumors. Endocr Rev 2001;22:836-58.
33. Vejda S, Erlach N, Peter B, Drucker C, Rossmanith W, Pohl J et al. Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis 2003;24:1801-9.
34. Mashima H, Kanzaki M, Nobusawa R, Zhang YQ, Suzuki M, Mine T et al. Derangements in the activin-follistatin system in hepatoma cells. Gastroenterology 1995;108:834-40.
35. Rossmanith W, Chabicovsky M, Grasl-Kraupp B, Peter B, Schausberger E, Schulte-Hermann R. Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control. Mol Carcinog 2002;35:1-5.
36. Takabe K, Lebrun JJ, Nagashima Y, Ichikawa Y, Mitsuhashi M, Momiyama N et al. Interruption of activin A autocrine regulation by antisense oligodeoxynucleotides accelerates liver tumor cell proliferation. Endocrinology 1999;140:3125-32.
37. Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, Gillett NA. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology (Baltimore, MD) 1994;20:854-62.
38. Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology (Baltimore, MD) 1993;18:347-56.
39. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T et al. Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Investig 1993;92:1491-6.
40. Kogure K, Omata W, Kanzaki M, Zhang YQ, Yasuda H, Mine T et al. A single intraportal administration of follistatin accelerates liver regeneration in partially hepatectomized rats. Gastroenterology 1995;108:1136-42.
41. Kogure K, Zhang YQ, Kanzaki M, Omata W, Mine T, Kojima I. Intravenous administration of follistatin: delivery to the liver and effect on liver regeneration after partial hepatectomy. Hepatology (Baltimore, MD) 1996;24:361-6.
42. Kogure K, Zhang YQ, Maeshima A, Suzuki K, Kuwano H, Kojima I. The role of activin and transforming growth factor-beta in the regulation of organ mass in the rat liver. Hepatology (Baltimore, MD) 2000;31:916-21.
43. Takabe K, Wang L, Leal AM, Macconell LA, Wiater E, Tomiya T et al. Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats. Hepatology (Baltimore, MD) 2003;38:1107-15.
44. Endo D, Maku-Uchi M, Kojima I. Activin or follistatin: which is more beneficial to support liver regeneration after massive hepatectomy? Endocr J 2006;53:73-8.
45. Endo D, Kogure K, Hasegawa Y, Maku-uchi M, Kojima I. Activin A augments vascular endothelial growth factor activity in promoting branching tubulogenesis in hepatic sinusoidal endothelial cells. J Hepatol 2004;40:399-404.
46. Grusch M, Drucker C, Peter-Vorosmarty B, Erlach N, Lackner A, Losert A et al. Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol 2006;45:673-80.
47. Ichikawa T, Zhang YQ, Kogure K, Hasegawa Y, Takagi H, Mori M et al. Transforming growth factor beta and activin tonically inhibit DNA synthesis in the rat liver. Hepatology Baltimore, MD) 2001;34:918-25.
48. Kanamaru C, Yasuda H, Takeda M, Ueda N, Suzuki J, Tsuchida T et al. Smad7 is induced by norepinephrine and protects rat hepatocytes from activin A-induced growth inhibition. J Biol Chem 2001;276:45636-41.
49. Ji GZ, Wang XH, Miao L, Liu Z, Zhang P, Zhang FM et al. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. World J Gastroenterol 2006;12:644-8.
50. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999;18:4879-83.
51. De Bleser PJ, Niki T, Xu G, Rogiers V, Geerts A. Localization and cellular sources of activins in normal and fibrotic rat liver. Hepatology (Baltimore, MD) 1997;26:905-12.
52. Loria P, Petraglia F, Concari M, Bertolotti M, Martella P, Luisi S et al. Influence of age and sex on serum concentrations of total dimeric activin A. Eur J Endocrinol 1998;139:487-92.